Gene therapy developer Krystal Biotech sets terms for $30 million IPO – Nasdaq
|
Gene therapy developer Krystal Biotech sets terms for $30 million IPO
Nasdaq Krystal Biotech, a preclinical gene therapy biotech focused on dermatological diseases, announced terms for its IPO on Thursday. The Pittsburgh, PA-based company plans to raise $30 million by offering 3.0 million shares at a price range of $9 to $11. |
